GENFIT Share Price Deutsche Boerse AG
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.04 EUR | -3.26% |
|
-3.55% | +148.62% |
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 68Cr 77Cr 63Cr 58Cr 108.94Cr 7.41TCr 111.62Cr 751.93Cr 294.06Cr 3.66TCr 290.26Cr 283.96Cr 13TCr | P/E 2026 * |
35x | P/E 2027 * | 90.2x |
|---|---|---|---|---|---|
| Enterprise Value | 63Cr 71Cr 59Cr 54Cr 100.74Cr 6.85TCr 103.22Cr 695.35Cr 271.93Cr 3.39TCr 268.42Cr 262.59Cr 12TCr | EV / Sales 2026 * |
6.27x | EV / Sales 2027 * | 4.94x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -3.26% | ||
| 1 week | -3.55% | ||
| Current month | +24.19% | ||
| 1 month | +38.58% | ||
| 3 months | +61.99% | ||
| 6 months | +134.11% | ||
| Current year | +148.62% |
| 1 week | 13.04 |  | 13.48 |
| 1 month | 10.18 | | 14.02 |
| Current year | 5.08 | | 14.02 |
| 1 year | 3.01 | | 14.02 |
| 3 years | 2.8 | | 14.02 |
| 5 years | 2.74 | | 14.02 |
| 10 years | 2.74 | | 33.76 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.26% | -3.55% | - | - | 75Cr | |
| +2.61% | +1.91% | +1.70% | +13.91% | 4.79TCr | |
| -1.60% | -1.29% | +385.56% | +603.70% | 3.91TCr | |
| -0.98% | +2.68% | +11.10% | +45.34% | 3.67TCr | |
| +1.90% | +22.79% | +25.18% | +9.47% | 4.05TCr | |
| +1.47% | +4.90% | +6.48% | +43.52% | 2.8TCr | |
| -0.94% | -1.23% | - | - | 1.68TCr | |
| +2.44% | +10.02% | +29.11% | +129.56% | 1.59TCr | |
| +0.18% | -1.46% | +4.92% | +10.14% | 1.36TCr | |
| -1.14% | +6.94% | -6.05% | -29.33% | 1.38TCr | |
| Average | +0.07% | +4.66% | +57.25% | +103.29% | 2.8TCr | |
| Weighted average by Cap. | +0.60% | +5.06% | +73.07% | +124.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 11Cr 9.35Cr 8.58Cr 16Cr 1.09TCr 16Cr 110.9Cr 43Cr 540.47Cr 43Cr 42Cr 1.87TCr | 12Cr 14Cr 12Cr 11Cr 20Cr 1.35TCr 20Cr 137.3Cr 54Cr 669.11Cr 53Cr 52Cr 2.31TCr |
| Net income | 2.29Cr 2.6Cr 2.14Cr 1.96Cr 3.67Cr 249.38Cr 3.76Cr 25Cr 9.9Cr 123.41Cr 9.78Cr 9.56Cr 426.61Cr | 68L 77.39L 63.47L 58.25L 1.09Cr 74Cr 1.12Cr 7.53Cr 2.94Cr 37Cr 2.91Cr 2.84Cr 126.8Cr |
| Net Debt | -5.11Cr -5.82Cr -4.77Cr -4.38Cr -8.2Cr -557.21Cr -8.4Cr -57Cr -22Cr -275.73Cr -22Cr -21Cr -953.19Cr | -6.62Cr -7.53Cr -6.18Cr -5.67Cr -11Cr -721.33Cr -11Cr -73Cr -29Cr -356.94Cr -28Cr -28Cr -1.23TCr |
| Date | Price | Change |
|---|---|---|
| 29/26/29 | €13.04 | -3.26% |
| 28/26/28 | €13.48 | +0.45% |
| 27/26/27 | €13.42 | +2.44% |
| 24/26/24 | €13.10 | 0.00% |
| 23/26/23 | €13.10 | -6.56% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Select your edition
All financial news and data tailored to specific country editions
